Document Detail


Uremia enhances the blood pressure response to erythropoietin.
MedLine Citation:
PMID:  9140703     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
To investigate the role of uremia in the development of human recombinant erythropoietin (r-HuEPO)-induced hypertension, Wistar rats were divided into a uremic (subtotal nephrectomy) and a control group. After three weeks, both groups were again divided and each subgroup received either r-HuEPO (100 u/kg s.c., 3 times weekly) or the vehicle for a further 3 weeks. Hematocrit, blood pressure and blood chemistry were measured prior to surgery, before either vehicle or r-HuEPO treatment and before euthanasia. The uremic group developed anemia, hypertension and all the biochemical features observed in humans with end-stage renal disease. r-HuEPO therapy increased hematocrit from 29 +/- 2.5% to 46 +/- 2% (p < 0.01) in the uremic rats. The mean baseline blood pressure was 119 +/- 10 mmHg. At week 3, mean blood pressure was unchanged in control rats, but it was increased to 151 +/- 5 mmHg (p < 0.01) in the nephrectomized group. At week 6, mean blood pressure in the untreated uremic rats remained unchanged from week 3, but blood pressure in the uremic animals treated with r-HuEPO increased significantly to 187 +/- 8 mmHg (p < 0.01). There was no significant correlation between hematocrit and blood pressure in the r-HuEPO treated uremic group (r = 0.01, NS). r-HuEPO had no effect on blood pressure in control rats despite a significant increase in hematocrit. These results indicate that the blood pressure response to r-HuEPO is enhanced in rats with chronic renal failure.
Authors:
S Lacasse-M; I Kingma; R Larivière; J H Grose; M Lebel
Related Documents :
12900043 - Effect of dorsal periaqueductal gray lesion on cardiovascular and behavioural responses...
12819223 - Selected contribution: effects of aging on cerebrovascular tone and [ca2+]i.
22743783 - Performance of different peep valves and helmet outlets at increasing gas flow rates: a...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical and experimental hypertension (New York, N.Y. : 1993)     Volume:  19     ISSN:  1064-1963     ISO Abbreviation:  Clin. Exp. Hypertens.     Publication Date:  1997 May 
Date Detail:
Created Date:  1997-07-10     Completed Date:  1997-07-10     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9305929     Medline TA:  Clin Exp Hypertens     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  389-401     Citation Subset:  IM    
Affiliation:
Department of Nephrology and Reseach Centre, L'Hôtel-Dieu de Québec Hospital, P.Q., Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Blood Pressure / drug effects*
Creatinine / blood
Erythropoietin / pharmacology*
Hematocrit
Humans
Male
Nephrectomy
Rats
Rats, Wistar
Recombinant Proteins
Reference Values
Systole
Uremia / blood,  physiopathology*
Chemical
Reg. No./Substance:
0/Recombinant Proteins; 11096-26-7/Erythropoietin; 60-27-5/Creatinine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Biochemical and physiological evidence that carnosine is an endogenous neuroprotector against free r...
Next Document:  Newborn organ weight and spontaneous hypertension: recombinant inbred strain study.